Pharmaceutical composition for prevention or treatment of nontuberculous mycobacteria infection comprising CD36 inhibitor

A CD36 inhibitor-based pharmaceutical composition and health functional food effectively address the limitations of current treatments for non-tuberculous mycobacterial infections by inhibiting bacterial growth and proliferation, providing a promising alternative with reduced side effects and improved efficacy.

WO2024237696A1PCT designated stage expired Publication Date: 2024-11-21KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006643
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-14
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for non-tuberculous mycobacterial infections, particularly those caused by M. avium complex (MAC) and M. abscessus, are inadequate, leading to high virulence and resistance, especially in middle-aged and older women with low body mass index, with existing antibiotics causing significant side effects and limited efficacy in preventing disease progression.

Method used

Development of a pharmaceutical composition and health functional food containing a CD36 inhibitor, such as sulfo-N-succinimidyl oleate (SSO) derivatives, which inhibit the expression or activity of cluster of differentiation 36 (CD36), thereby reducing fatty acid uptake by non-tuberculous mycobacteria, thereby inhibiting their growth and proliferation.

Benefits of technology

The CD36 inhibitor effectively suppresses the growth and proliferation of non-tuberculous mycobacteria, offering a potential treatment option with reduced side effects and improved efficacy compared to traditional antibiotics, as demonstrated by experiments showing inhibited bacterial growth and reduced bacterial load in animal models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006643_21112024_PF_FP_ABST
    Figure KR2024006643_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of nontuberculous mycobacteria infection. A CD36 inhibitor, sulfo-N-succinimidyl oleate (SSO), and SSO derivatives, according to an aspect of the present invention, have the effect of inhibiting the growth, proliferation and the like of nontuberculous mycobacteria, and thus can be effectively used in the prevention or treatment of nontuberculous mycobacteria infection or nontuberculous mycobacteria pulmonary disease.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for the prevention or treatment of nontuberculous mycobacterial infections comprising a CD36 inhibitor

[0001] It relates to a pharmaceutical composition for the prevention or treatment of nontuberculous mycobacterial infections.

[0002] Mycobacterium species are divided into two groups based on their degree of pathogenicity and infectivity to the host: the tuberculosis group, which includes Mycobacterium tuberculosis and Mycobacterium leprae, which are obligate pathogens, and the nontuberculous mycobacteria (NTM), which are opportunistic pathogens.

[0003] Nontuberculous mycobacteria are widely distributed in nature, and the virulence of causing disease varies depending on the species. Specifically, Mycobacterium avium complex (MAC), Mycobacterium abscessus (MAB), and Mycobacterium kansasii are relatively virulent, while Mycobacterium fortuitum is relatively less virulent. Diseases caused by nontuberculous mycobacteria are broadly classified into four characteristic clinical syndromes: pulmonary disease, lymphadenitis, skin, soft tissue, and bone infections, and disseminated disease. Of these, pulmonary disease is the most common form, accounting for more than 90% of all cases.

[0004] Reports of lung disease caused by nontuberculous mycobacteria (NTM) have been increasing since 2000, with MAC currently the most frequently reported causative agent in most developed countries. In Korea, MAC accounts for approximately 70-80% of all nontuberculous mycobacterial lung disease cases, with MAB being the second most common causative agent. These NTM-induced lung diseases are characterized by symptoms such as cough, fever, hemoptysis, and sputum production.

[0005] Nontuberculous mycobacteria are ubiquitous in the natural environment, leading to periodic exposure to them in people's daily lives. However, respiratory infections and clinical illnesses are reported to occur more frequently in middle-aged and older women with low body mass indexes. Recent clinical reports indicate that these patients are more likely to experience disease exacerbation and mortality, as well as to have refractory outcomes despite long-term antibiotic treatment.

[0006] Unlike pulmonary tuberculosis, the treatment effect of lung disease caused by the above-mentioned nontuberculous mycobacteria is still not satisfactory despite combined antibiotic treatment. In addition, since the age group in which the disease occurs is mainly middle-aged or older, the side effects that accompany various antibiotics and various treatment methods are high.

[0007] Meanwhile, CD36 (HGNC:1663, EntrezGene:948, Ensembl:ENSG00000135218, OMIM: 173510, UniProtKB: P16671) is a receptor protein known for several diverse functions, as indicated by its various other names. In particular, CD36 is known as a fatty acid translocase.

[0008] Meanwhile, sulfo-N-succinimidyl oleate (SSO) is known as a CD36 inhibitor.

[0009] Accordingly, the present inventors confirmed that MAC, an intracellular pathogen, utilizes the lipid resources of the host cell for survival and replication, and completed the present invention by confirming that a CD36 inhibitor, SSO, and a newly synthesized SSO derivative inhibit MAC growth within the host cell by inhibiting fatty acid uptake.

[0010] One aspect of the present invention provides a sulfo-N-succinimidyl oleate (SSO) derivative, or a stereoisomer, racemate, solvate, or salt thereof.

[0011] Another aspect is to provide a compound of formula I, or a stereoisomer, racemate, solvate, or salt thereof.

[0012] Another aspect provides a pharmaceutical composition for preventing or treating nontuberculous mycobacterial infection or nontuberculous mycobacterial lung disease, comprising an inhibitor of the expression or activity of CD36 (cluster of differentiation 36).

[0013] Another aspect is to provide a health functional food for preventing or improving nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease, comprising an inhibitor of CD36 (cluster of differentiation 36) expression or activity.

[0014] Another aspect provides a method for preventing or treating nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease, comprising administering to a subject in need thereof an inhibitor of the expression or activity of CD36 (cluster of differentiation 36).

[0015] Another aspect provides the use of a CD36 (cluster of differentiation 36) expression or activity inhibitor for preventing, treating or ameliorating nontuberculous mycobacterial infections or nontuberculous mycobacterial lung diseases.

[0016] Another aspect provides the use of an inhibitor of the expression or activity of CD36 (cluster of differentiation 36) for the manufacture of a pharmaceutical composition for the prevention or treatment of nontuberculous mycobacterial infections or nontuberculous mycobacterial pulmonary diseases.

[0017] Another aspect provides the use of a CD36 (cluster of differentiation 36) expression or activity inhibitor for the manufacture of a health functional food for preventing or improving nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease.

[0018] One aspect of the present invention provides a sulfo-N-succinimidyl oleate (SSO) derivative, or a stereoisomer, racemate, solvate, or salt thereof.

[0019] Another aspect provides a compound of formula I, or a stereoisomer, racemate, solvate, or salt thereof:

[0020] [Chemical Formula I]

[0021]

[0022] In the above formula,

[0023] X is -CH2-, -O-, or -S-;

[0024] R 1 Silver -H, C 1-6 Alkyl, C 1-6 is alkoxy or halogen;

[0025] R 2 is -H, halogen, -OR 4 , -SR 4 , or -COOR 4 And,

[0026] The above R 4 are each independently -H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 It is alkynyl;

[0027] R 3 C is substituted or unsubstituted 8-22 Alkyl or C 8-22 It is alkenyl,

[0028] C here 8-22 Alkyl or C 8-22 When alkenyl is substituted, C8-22 Alkyl or C 8-22 Each hydrogen atom of the alkenyl is independently C 1-12 Alkyl, C 2-12 alkenyl, and C 2-12 It is substituted with one or more selected from the group consisting of alkynyl.

[0029] The above sulfo-N-succinimidyl oleate derivative may be a compound of the above chemical formula I.

[0030] In one embodiment, the compound of formula I, or a stereoisomer, racemate, solvate, or salt thereof, may be a CD36 (cluster of differentiation 36) inhibitor, specifically an inhibitor of CD36 expression or activity.

[0031] The above CD36 expression or activity inhibitor may be a substance that reduces the expression of the CD36 gene or the activity of the CD36 protein.

[0032] In one embodiment, the CD36 expression or activity inhibitor may inhibit the growth, proliferation, or infection of nontuberculous mycobacteria. The inhibition of growth, proliferation, or infection may occur through inhibition of cellular fatty acid uptake.

[0033] The term “stereoisomer” as used herein refers to an isomer that arises due to differences in the spatial arrangement of atoms or atomic groups within a molecule, and includes both optical isomers and geometric isomers. Optical isomers are a pair of mirror images of four atoms or atomic groups bonded to an asymmetric carbon atom depending on the bonding method, and if there are two asymmetric carbon atoms within a molecule, it becomes a diastereoisomer, and all stereoisomers that may arise depending on the number of asymmetric carbon atoms may be included. In addition, when an unsaturated hydrocarbon is present, a geometric isomer is formed, and all geometric isomers that may arise may also be included.

[0034] As used herein, the term “racemate” means a substance in which equal amounts of the right-handed (R) optical isomer and the left-handed (S) optical isomer of a chiral molecule are mixed and thus do not exhibit optical activity.

[0035] As used herein, the term "solvate" refers to a molecular complex between a compound according to the present invention and solvent molecules, and may mean a compound according to the present invention or a salt thereof containing a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Examples of solvates include, but are not limited to, a compound according to the present invention bound to water, isopropanol, ethanol, methanol, dimethylsulfoxide, ethyl acetate, acetic acid, ethanolamine, or a mixed solvent thereof.

[0036] Additionally, it may be convenient or desirable to prepare, purify, and / or handle a corresponding solvate of the compound. The term "solvate" may be used herein in its conventional sense to refer to a complex of a solute (e.g., a compound, a salt of the compound) and a solvent. When the solvent is water, the solvate may conveniently be referred to as a hydrate, such as a monohydrate, dihydrate, trihydrate, etc.

[0037] In one embodiment, in the above formula I, X can be -CH2-, -O- or -S-.

[0038] In one embodiment, in the above formula I, X can be -CH2- or -O-.

[0039] In one embodiment, in the chemical formula I, R 1 Silver -H, or C 1-6 It could be an alkyl.

[0040] In one embodiment, in the chemical formula I, R 1 can be -H.

[0041] In one embodiment, in the chemical formula I, R 2 is -OR 4 , or -COOR 4 and the above R 4 are each independently -H or C 1-6 It could be an alkyl.

[0042] In one embodiment, in the chemical formula I, R 2 is -OR 4 , or -COOR 4 and the above R 4 are each independently -H or C 1-6 It could be an alkyl.

[0043] In one embodiment, in the chemical formula I, R 2 is -COOR 4 and the above R 4 are each independently -H or C 1-6 It could be an alkyl.

[0044] In one embodiment, in the chemical formula I, R 2 is -COOR 4 and the above R 4 can be -H.

[0045] In one embodiment, in the chemical formula I, R 3 Silver is unsubstituted C 8-22 Alkyl or C 8-22 It could be alkenyl.

[0046] In one embodiment, in the chemical formula I, R 3 may be an unsubstituted alkenyl.

[0047] In one embodiment, in the above formula I, X is -CH2-, -O- or -S-; R 1 Silver -H, or C 1-6 is alkyl; R 2 is -OR 4 , or -COOR 4 and the above R 4 are each independently -H or C 1-6is alkyl; R 3 Silver is unsubstituted C 8-22 Alkyl or C 8-22 It could be alkenyl.

[0048] In one embodiment, in the above formula I, X is -CH2- or -O-; R 1 Silver -H, or C 1-6 is alkyl; R 2 is -OR 4 , or -COOR 4 and the above R 4 are each independently -H or C 1-6 is alkyl; R 3 Silver is unsubstituted C 8-22 Alkyl or C 8-22 It could be alkenyl.

[0049] In one embodiment, in the above formula I, X is -CH2-, -O- or -S-; R 1 is -H; R 2 is -COOR 4 and the above R 4 are each independently -H or C 1-6 is alkyl; R 3 Silver is unsubstituted C 8-22 Alkyl or C 8-22 It could be alkenyl.

[0050] In one embodiment, in the above formula I, X is -CH2-, -O- or -S-; R 1 is -H; R 2 is -COOR 4 and the above R 4 are each independently -H or C 1-6 is alkyl; R 3 Silver is unsubstituted C 8-22 It could be alkenyl.

[0051] In one embodiment, in the above formula I, X is -CH2- or -O-; R 1 is -H; R 2 is -COOR 4 and the above R 4are each independently -H or C 1-6 is alkyl; R 3 Silver is unsubstituted C 8-22 It could be alkenyl.

[0052] In one embodiment, R of the chemical formula I 3 It can be an aliphatic chain of a saturated fatty acid having 8 to 22 carbon atoms or an unsaturated fatty acid having 8 to 22 carbon atoms.

[0053] In one embodiment, the saturated fatty acid may be selected from the group consisting of caprylic acid, pelargonic acid, capric acid, neodecanoic acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecanoic acid, palmitic acid, margaric acid, stearic acid, isostearic acid, nonadecylic acid, arachidic acid, heneicosylic acid, and behenic acid.

[0054] In one embodiment, the saturated fatty acid may be selected from the group consisting of myristic acid, pentadecanoic acid, palmitic acid, margaric acid, stearic acid, isostearic acid, nonadecylic acid, and arachidic acid.

[0055] In one embodiment, the saturated fatty acid may be selected from the group consisting of palmitic acid, margaric acid, stearic acid, isostearic acid, nonadecylic acid, and arachidic acid.

[0056] In one embodiment, the saturated fatty acid may be selected from the group consisting of margaric acid, stearic acid, isostearic acid, and nonadecylic acid.

[0057] In one embodiment, the saturated fatty acid may be selected from the group consisting of stearic acid and isostearic acid.

[0058] In one embodiment, the unsaturated fatty acid is lauroleic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, gadoleic acid, eicosenoic acid, erucic acid, linoleic acid, eicosadienoic acid, docosadienoic acid, α-linolenic acid, γ-linolenic acid, α-eleostearic acid, β-eleostearic acid, columbinic acid, pinolenic acid, It may be selected from the group consisting of mead acid, eicosatrienoic acid, stearidonic acid, arachidonic acid, eicosatetraenoic acid, and docosatetraenoic acid.

[0059] In one embodiment, the unsaturated fatty acid may be selected from the group consisting of palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, α-eleostearic acid, β-eleostearic acid, columbinic acid, pinolenic acid, and stearidonic acid.

[0060] In one embodiment, the unsaturated fatty acid may be selected from the group consisting of oleic acid, elaidic acid, vaccenic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, α-eleostearic acid, β-eleostearic acid, columbinic acid, and pinolenic acid.

[0061] In one embodiment, the unsaturated fatty acid may be selected from the group consisting of palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, gadoleic acid, and eicosenoic acid.

[0062] In one embodiment, the unsaturated fatty acid may be selected from the group consisting of oleic acid, elaidic acid, and vaccenic acid.

[0063] In one embodiment, the unsaturated fatty acid may be oleic acid.

[0064] In one embodiment, R of the chemical formula I 2 may have an arrangement as shown in the following chemical formula II:

[0065] [Chemical Formula II]

[0066] .

[0067] In one embodiment, the compound of formula I may be a compound selected from the group consisting of:

[0068] (S)-1-oleoyl-5-oxopyrrolidine-2-carboxylic acid,

[0069] (R)-1-oleoyl-5-oxopyrrolidine-2-carboxylic acid,

[0070] (S)-3-oleoyl-2-oxooxazolidine-4-carboxylic acid and

[0071] (R)-3-Oleoyl-2-oxooxazolidine-4-carboxylic acid.

[0072] In one embodiment, the compound of formula I may be a compound selected from the group consisting of:

[0073] (S)-1-oleoyl-5-oxopyrrolidine-2-carboxylic acid, and

[0074] (S)-3-Oleoyl-2-oxooxazolidine-4-carboxylic acid.

[0075] Another aspect provides a pharmaceutical composition for preventing or treating nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease, comprising an inhibitor of the expression or activity of CD36 (cluster of differentiation 36).

[0076] Another aspect provides a method for preventing or treating nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease, comprising administering to a subject in need thereof an inhibitor of the expression or activity of CD36 (cluster of differentiation 36).

[0077] Another aspect provides the use of an inhibitor of the expression or activity of CD36 (cluster of differentiation 36) for preventing, treating or ameliorating nontuberculous mycobacterial infections or nontuberculous mycobacterial lung diseases.

[0078] Another aspect provides the use of an inhibitor of the expression or activity of CD36 (cluster of differentiation 36) for the manufacture of a pharmaceutical composition for the prevention or treatment of nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease.

[0079] In one embodiment, the pharmaceutical composition may comprise an inhibitor of CD36 expression or activity as an active ingredient.

[0080] A CD36 expression or activity inhibitor refers to a substance that reduces the expression of the CD36 gene or the activity of the CD36 protein.

[0081] In one embodiment, the inhibitor of the present specification that suppresses the expression of the CD36 gene refers to a substance that reduces the expression level or activity of the CD36 gene by directly acting on the CD36 gene or indirectly acting on an upstream regulator of the CD36 gene to reduce the expression of the CD36 gene at the transcriptional level, increase the degradation of the expressed CD36 gene, or interfere with its activity.

[0082] Specifically, in one embodiment, the CD36 expression or activity inhibitor may be one or more selected from the group consisting of, but not limited to, an antisense nucleotide that complementarily binds to the mRNA of the CD36 gene, a small hairpin RNA (shRNA), a small interfering RNA (siRNA), a microRNA (miRNA), and a ribozyme.

[0083] As used herein, the term "antisense nucleotide" refers to a DNA or RNA sequence complementary to a specific gene and capable of binding to CD36 mRNA. Because antisense nucleotides are long chains of monomer units, they can be easily synthesized against a target gene sequence.

[0084] As used herein, the term "siRNA (small interfering RNA)" refers to a short double-stranded RNA that can induce RNA interference (RNAi) by cleaving a specific mRNA. siRNA comprises a sense RNA strand with a sequence homologous to the mRNA of a target gene and an antisense RNA strand with a sequence complementary to that sequence. siRNA can suppress target gene expression and is therefore used in gene knockdown methods and gene therapy.

[0085] In this specification, the term "shRNA (short hairpin RNA)" is a single-stranded RNA that is divided into a stem portion that forms a double-stranded portion by hydrogen bonding and a loop portion that has a ring shape, and is processed by a protein such as Dicer to be converted into siRNA and can perform the same function as siRNA.

[0086] As used herein, the term "miRNA (microRNA)" refers to 21 to 23 non-coding RNAs that regulate gene expression post-transcriptionally by promoting the degradation of target RNAs or inhibiting their translation.

[0087] As used herein, the term "ribozyme" refers to an RNA molecule with enzyme-like functionality that recognizes a specific base sequence and cleaves it on its own. A ribozyme consists of a region that specifically binds to a complementary base sequence of a target messenger RNA strand and a region that cleaves the target RNA.

[0088] Additionally, in one embodiment, the inhibitor that inhibits the activity of the CD36 protein of the present disclosure may be one or more selected from the group consisting of antibodies, antigen-binding fragments of antibodies, compounds, peptides, peptide mimetics, aptamers, and fusion proteins that specifically bind to the CD36 protein, but are not limited thereto.

[0089] Specifically, in one embodiment, the CD36 expression or activity inhibitor may be one or more selected from the group consisting of, but not limited to, antibodies, antigen-binding fragments of antibodies, compounds, peptides, peptide mimetics, aptamers, and fusion proteins that specifically bind to CD36 protein.

[0090] In one embodiment, the CD36 expression or activity inhibitor may be one or more selected from the group consisting of, but not limited to, antibodies, antigen-binding fragments of antibodies, and compounds that specifically bind to CD36 protein.

[0091] The term "antibody" refers to an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combination thereof. As used herein, the term "antibody" encompasses polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, fully human antibodies, recombinant antibodies, bispecific antibodies, fusion proteins comprising full-length antibodies or fragments thereof, fragments of such antibodies, and any other modified immunoglobulin molecule, so long as it exhibits the desired biological activity. Antibodies can be any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or their subclasses (isotypes) (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), based on the identity of their heavy chain constant domains, designated α, δεγ, and μ, respectively. Different classes of immunoglobulins have distinct subunit structures and three-dimensional conformations. Antibodies may be naked or conjugated to other molecules, such as toxins or radioisotopes.

[0092] The term "antibody fragment" refers to a portion of an intact antibody. "Antigen-binding fragment," "antigen-binding domain," or "antigen-binding region" refers to the portion of an antibody that binds to an antigen. An antigen-binding fragment may contain an antigenic determining region (e.g., a complementarity determining region (CDR)) of an antibody. Examples of antigen-binding fragments of antibodies include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, and single-chain antibodies. Antigen-binding fragments of antibodies may be derived from any animal species, such as rodents (e.g., mice, rats, or hamsters) and humans, or may be artificially produced.

[0093] The terms "anti-CD36 antibody," "CD36 antibody," and "antibody that binds to CD36" refer to an antibody that binds to CD36 with sufficient affinity to be useful as a therapeutic agent targeting CD36. The extent of binding of the anti-CD36 antibody to a non-related, non-CD36 protein may be less than about 10% of the antibody's binding to CD36, for example, as measured by radioimmunoassay (RIA).

[0094] As used herein, the term “compound” includes any compound capable of specifically binding to the CD36 protein and inhibiting its activity.

[0095] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acids of any length. The polymer may be linear or branched, may contain modified amino acids, and may contain interrupted non-amino acids. The term also encompasses amino acid polymers that are naturally modified or modified by any other manipulation or modification, such as disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or conjugation with a labeling moiety. This definition also encompasses polypeptides having, for example, one or more amino acid analogs (e.g., unnatural amino acids, etc.), as well as other modifications known in the art. Since the polypeptides herein are antibody-based, it is understood that in certain embodiments, the polypeptides may be produced as single chains or as conjugated chains.

[0096] As used herein, the term "peptide mimetics" inhibits the activity of CD36 protein by inhibiting the binding domain of the CD36 protein. A peptide mimetic can be a peptide or a non-peptide, and can be composed of amino acids joined by non-peptide bonds, such as psi bonds. It can also be a "conformationally constrained" peptide, a cyclic mimetic, or a cyclic mimetic comprising at least one exocyclic domain, a binding moiety (binding amino acids), and an active site. A peptide mimetic can be a novel small molecule that is structured similarly to the secondary structure characteristics of the CD36 protein and can mimic the inhibitory properties of larger molecules, such as antibodies or soluble receptors, and can act with effects equivalent to natural antagonists.

[0097] As used herein, the term "aptamer" refers to a single-stranded nucleic acid (DNA, RNA, or modified nucleic acid) that has a stable tertiary structure in itself and has the characteristic of being able to bind to a target molecule with high affinity and specificity.

[0098] As used herein, the term "fusion protein" refers to a new protein created by combining two or more different proteins or homologous proteins. It is also often called a chimera protein. Two or more heterologous proteins combine in part, part, or whole. In many cases, the sequence of one gene is spliced ​​with the sequence of another gene, with codons aligned, to create a hybrid gene that is expressed and produced as a protein.

[0099] In one embodiment, a fusion protein according to the present disclosure may comprise a fragment of CD36 that specifically binds to the CD36 protein.

[0100] In one embodiment, the CD36 expression or activity inhibitor may comprise one or more selected from the group consisting of:

[0101] (i) antisense nucleotides, small hairpin RNA (shRNA), small interfering RNA (siRNA), microRNA (miRNA), and ribozyme that complementarily bind to the mRNA of the CD36 gene; and

[0102] (ii) Antibodies, antigen-binding fragments of antibodies, compounds, peptides, peptide mimetics, aptamers, and fusion proteins that bind to CD36 protein.

[0103] In one embodiment, the compound may be sulfo-N-succinimidyl oleate (SSO) or a derivative thereof.

[0104] In one embodiment, the CD36 expression or activity inhibitor may be sulfo-N-succinimidyl oleate (SSO) or a derivative thereof.

[0105] In one embodiment, the derivative of sulfo-N-succinimidyl oleate (SSO) may be a compound according to the present disclosure, or a stereoisomer, racemate, solvate, or salt thereof. Specifically, the compound according to the present disclosure may refer to a compound described in relation to Chemical Formula I of the present disclosure.

[0106] The above sulfo-N-succinimidyl oleate (SSO) or a derivative thereof can specifically bind to the CD36 protein and inhibit its activity. Specifically, sulfo-N-succinimidyl oleate (SSO) or a derivative thereof not only specifically binds to the CD36 protein, but also inhibits the fatty acid uptake activity of CD36, thereby inhibiting the growth, proliferation, or infection of nontuberculous mycobacteria.

[0107] The term "comprising as an active ingredient" in this specification means including an effective amount capable of exhibiting a preventive or therapeutic effect on nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease of the pharmaceutical composition.

[0108] In a pharmaceutical composition according to one embodiment, the salt may be a pharmaceutically acceptable salt.

[0109] As used herein, the term “pharmaceutically acceptable” means a substance that can be effectively used for a desired purpose without causing excessive toxicity, irritation, or allergic reaction, within the scope of pharmaceutical judgment.

[0110] As used herein, the term "pharmaceutically acceptable salt" means a salt according to one aspect of the present invention which is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. Salts of the parent compound can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid form of these compounds with a stoichiometric amount of a suitable base, for example, sodium, calcium, magnesium or potassium, or by reacting the free base form of these compounds with a stoichiometric amount of a suitable acid. These reactions are typically carried out in water or in an organic solvent or in a mixture of the two. Generally, when practical, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile can be used. The pharmaceutically acceptable salts include both addition salts of acids or bases and stereochemically isomeric forms thereof, and may be, for example, addition salts of organic or inorganic acids. The above salt includes any salt that maintains the activity of the parent compound in the subject of administration and does not cause undesirable effects, and is not particularly limited thereto.

[0111] These salts include inorganic and organic salts, for example, acetic acid, nitric acid, aspartic acid, sulfonic acid, sulfuric acid, maleic acid, glutamic acid, formic acid, succinic acid, phosphoric acid, phthalic acid, tannic acid, tartaric acid, hydrobromic acid, propionic acid, benzenesulfonic acid, benzoic acid, stearic acid, lactic acid, bicarboxylic acid, bisulfuric acid, bitartaric acid, oxalic acid, butyric acid, calcium idet, carbonic acid, chlorobenzoic acid, citric acid, idetic acid, toluenesulfonic acid, fumaric acid, gluceptic acid, esilinic acid, pamoic acid, gluconic acid, methylnitric acid, malonic acid, hydrochloric acid, hydroiodoic acid, hydroxynaphtholic acid, isethionic acid, lactobionic acid, mandelic acid, mucic acid, It can be naphthylic acid, muconic acid, p-nitromethanesulfonic acid, hexamic acid, pantothenic acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, salicylic acid, sulfamic acid, sulfanilinic acid, methanesulfonic acid. In addition, the salt form includes salts of alkali and alkaline earth metals such as ammonium salt, lithium salt, sodium salt, potassium salt, magnesium salt, and calcium salt, salts with organic bases such as benzathine, N-methyl-D-glucamine, and hydrabamine salts, and salts with amino acids such as arginine and lysine. In addition, the salt form can be converted into a free form by treating with a suitable base or acid.

[0112] In this specification, the term “prevention” means any action that inhibits or delays the onset of a target disease, “treatment” means any action that improves or beneficially changes a target disease and its metabolic abnormality symptoms by administering a pharmaceutical composition according to the present invention, and “improvement” means any action that reduces a parameter related to a target disease, for example, the severity of a symptom, by administering a composition according to the present invention.

[0113] In a pharmaceutical composition according to one embodiment, the CD36 expression or activity inhibitor may inhibit the growth, proliferation, or infection of nontuberculous mycobacteria. The inhibition of growth, proliferation, or infection may occur through inhibition of fatty acid uptake by cells.

[0114] In one embodiment, the nontuberculous mycobacterium is Mycobacterium avium (Mav), Mycobacterium abscessus subsp. abscessus (Mabc), Mycobacterium abscessus subsp. massiliense (Mmass), Mycobacterium abscessus subsp. boletii.bolletii), Mycobacterium Intracellurare, Mycobacterium chimaera, Mycobacterium Scrofulaceum, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium peregrinum, Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium Genevans, Mycobacterium simiae, Mycobacterium terrae, It may be at least one selected from the group consisting of Mycobacterium nonchromogenicum, Mycobacterium celatum, Mycobacterium gordonae, Mycobacterium szulgai, Mycobacterium mucogenicum, Mycobacterium xenopi, and Mycobacterium aubagnens. The nontuberculous mycobacteria may be multidrug-resistant (MDR) nontuberculous mycobacteria, examples of which include KMRC-010, KMRC-011, KMRC-012, and KMRC-013.

[0115] In one embodiment, the infection may include at least one selected from the group consisting of skin, soft tissue, and bone infections, lung diseases, lymphadenitis, and disseminated diseases.

[0116] In one embodiment, the pharmaceutical composition may further comprise an antimycobacterial agent or an antituberculosis agent or may be administered in combination with an antimycobacterial agent or an antituberculosis agent.

[0117] In one embodiment, the acid-fast bactericidal agent or antituberculosis agent is rifampicin, rifabutin, rifapentine, pyrazinamide, ciprofloxacin, capeomycin, fluoroquinolone, cycloserine, ethambutol, amoxicillin / clavulanate, ofloxacin, levofloxacin, isoniazid, streptomycin, kanamycin, prothionamide, moxifloxacin, amikacin, protionamide, It may be at least one selected from the group consisting of ethionamide, cycloserine, thioacetazone, clofazimine, derivatives of dianomidiphenylsulphone, clarithromycin, azithromycin, and linezolid.

[0118] Additionally, co-administration with one or more additional therapeutic agents includes simultaneous or sequential administration in any order.

[0119] Specifically, “combination administration” as used herein can be achieved by administering individual components of a treatment regimen simultaneously, sequentially, in reverse order, or individually. Combination therapy is defined as obtaining a combination treatment effect by administering two or more drugs simultaneously, sequentially, or in reverse order, or by administering them alternately at regular or indefinite intervals, and combination therapy is not limited thereto, but can be defined as providing a synergistic effect while being therapeutically superior to the efficacy obtained by administering one or the remaining components of the combination therapy at a regular dose, as measured by, for example, the degree of response, the rate of response, the time until disease progression, or the duration of survival.

[0120] Combination therapy can provide a "synergistic effect," i.e., the effect achieved when the active substances are used together is greater than the sum of the effects achieved when the active substances are used individually. A synergistic effect can be achieved when the active substances are (1) co-formulated and combined in a unit dosage form and administered or delivered simultaneously; (2) delivered as separate formulations sequentially, alternately, or in parallel; or (3) by some other route of administration. When delivered in alternating therapy, a synergistic effect can be achieved when the active substances are administered or delivered sequentially, for example, by each injection using a separate syringe. A "synergistic combination" produces an effect that is superior to the sum of the effects of the individual active substances of the combination.

[0121] Combination therapy can provide an "additive" effect, meaning that the effect achieved when the active substances are used together is equal to the sum of the effects achieved when the active substances are used separately.

[0122] The terms "subject" and "patient" are used interchangeably herein. The subject may be an animal. In some embodiments, the subject is a mammal, such as a non-human animal (e.g., a cow, pig, horse, cat, dog, rat, mouse, monkey, or other primate). In some embodiments, the subject is a cynomolgus monkey. In some embodiments, the subject is a human.

[0123] As used herein, the term "therapeutically effective amount" refers to an amount of a drug, e.g., an anti-CD36 antibody, effective to achieve a desired therapeutic or prophylactic result. In some cases, the desired result is treatment of a disease or disorder in a subject. The level of a therapeutically effective amount can be determined based on factors including the type and severity of the patient's disease, the activity and sensitivity of the drug to the drug, the time of administration, the route and excretion rate, the duration of treatment, concomitant medications, and other factors well known in the medical field. The compositions of the present disclosure can be administered as individual therapeutic agents or in combination with other therapeutic agents, can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered in single or multiple doses. That is, the total effective amount of the compositions of the present disclosure can be administered to a patient as a single dose, or can be administered in a fractionated treatment protocol in which multiple doses are administered over a long period of time. Taking all of the above factors into account, it is important to administer an amount that achieves the maximum effect with the minimum amount without causing side effects, and this can be readily determined by those skilled in the art.

[0124] As used herein, terms such as "treating," "treatment," "to treat," "palliating," or "to palliate" refer to therapeutic measures aimed at curing, slowing, alleviating symptoms, and / or arresting the progression of a diagnosed pathological condition or disorder. Therefore, those requiring treatment include those who have already been diagnosed with or are suspected of having a disorder.

[0125] Meanwhile, the composition of the present specification may additionally include a pharmaceutically acceptable carrier and may be formulated together with the carrier.

[0126] As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not stimulate a living organism and does not inhibit the biological activity and properties of the administered compound. In a composition formulated as a liquid solution, acceptable pharmaceutical carriers include those that are sterile and biocompatible, such as saline solution, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.

[0127] The composition comprising the CD36 expression or activity inhibitor according to one embodiment of the present specification and a pharmaceutically acceptable carrier can be applied in any dosage form containing it as an active ingredient, and can be prepared as an oral or parenteral dosage form, and can be formulated in a unit dosage form for ease of administration and uniformity of dosage. The pharmaceutical dosage form of the present specification includes a form suitable for oral, rectal, nasal, topical (including buccal and sublingual), subcutaneous, vaginal, or parenteral (including intramuscular, subcutaneous, and intravenous) administration, or a form suitable for administration by inhalation or insufflation. The oral dosage form containing the composition of the present specification as an active ingredient can be formulated as, for example, a tablet, a troche, a lozenge, an aqueous or oily suspension, a prepared powder or granules, an emulsion, a hard or soft capsule, a syrup, or an elixir.

[0128] The composition of the present disclosure may be formulated as a parenteral dosage form containing the active ingredient, such as a subcutaneous injection, intravenous injection, or intramuscular injection; a suppository injection; or a spray formulation such as an aerosol that can be inhaled through the respiratory tract. To formulate the composition of the present disclosure as an injectable dosage form, the composition of the present disclosure may be mixed with a stabilizer or buffer in water to prepare a solution or suspension, which may then be formulated into a unit dosage form in an ampoule or vial.

[0129] The dosage of the pharmaceutical composition of this specification varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity. The daily dosage is preferably 0.01 μg to 100 mg per kg of body weight per day when administered parenterally, more preferably 1 μg to 50 mg. However, since the dosage may increase or decrease depending on the route of administration, severity of obesity, sex, body weight, age, etc., the above dosage does not limit the scope of this specification in any way.

[0130] Another aspect provides a health functional food for preventing or improving nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease, comprising an inhibitor of the expression or activity of CD36 (cluster of differentiation 36).

[0131] Another aspect provides the use of a CD36 (cluster of differentiation 36) expression or activity inhibitor for the manufacture of a health functional food for preventing or improving nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease.

[0132] In a health functional food according to one embodiment, the expression or activity inhibitor of CD36 (cluster of differentiation 36) is as described in relation to the pharmaceutical composition in the specification of the present invention.

[0133] In a health functional food according to an embodiment, non-tuberculous mycobacteria and infectious diseases are as described above.

[0134] In a health functional food according to one embodiment, the salt may be a salt acceptable from a food science perspective.

[0135] As used herein, the term "food-acceptable salt" refers to a formulation of a compound that does not cause serious irritation to an organism to which the compound is administered and does not impair the biological activity and physical properties of the compound. For example, the food-acceptable salt can be obtained by reacting the compound with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, sulfonic acid such as methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, capric acid, isobutanoic acid, malonic acid, succinic acid, phthalic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, and the like. In addition, it can be obtained by reacting the compound with a base to form salts such as ammonium salts, alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as calcium or magnesium salts, salts of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts of amino acids such as arginine and lysine, but is not limited thereto.

[0136] The health functional food herein may be formulated into any one form selected from the group consisting of powders, tablets, capsules, pills, granules, and liquids, using conventional methods known in the art, but is not limited thereto. Various forms may be manufactured using methods known in the art.

[0137] In addition, it can be prepared in the form of a composition by mixing with a known substance or active ingredient known to have preventive, ameliorating or therapeutic activity for nontuberculous mycobacterial infection or nontuberculous mycobacterial pulmonary disease.

[0138] In addition, the health functional food of the present invention may contain conventional food additives, and the suitability as the "food additive" is determined by the specifications and standards for the relevant item according to the general provisions and general test methods of the Food Additives Codex approved by the Ministry of Food and Drug Safety, unless otherwise specified. Items listed in the "Food Additives Codex" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, sorghum pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, alkaline agents added to noodles, preservative preparations, and tar color preparations.

[0139] In addition to the above, the health functional food of the present invention may include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present invention may include fruit pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients may be used independently or in combination.

[0140] According to one aspect of the present invention, the CD36 inhibitor, sulfo-N-succinimidyl oleate (SSO) and sulfo-N-succinimidyl oleate (SSO) derivatives have an effect of inhibiting the growth, proliferation, etc. of nontuberculous mycobacteria, and thus can be usefully used for the prevention or treatment of nontuberculous mycobacterial infections or nontuberculous mycobacterial pulmonary diseases.

[0141] Figure 1 is a graph confirming the growth inhibition efficacy of nontuberculous mycobacteria according to treatment with a CD36 inhibitor.

[0142] Figure 2 is a schematic diagram showing the production of a mouse animal model of respiratory infection induced by nontuberculous mycobacteria.

[0143] Figure 3 is a graph showing CFU in lung tissue of mice infected with nontuberculous mycobacteria-induced respiratory infection.

[0144] Figure 4 shows the results of fluorescent staining of lung tissue from a mouse infected with nontuberculous mycobacteria-induced respiratory infection.

[0145] Figure 5 is a graph showing fatty acid absorption capacity according to treatment of an SSO derivative according to one aspect of the present invention.

[0146] Figure 6 is a graph confirming the growth inhibition efficacy of non-tuberculous mycobacteria according to treatment with an SSO derivative according to one aspect of the present invention.

[0147] Hereinafter, preferred embodiments are presented to aid understanding of the present invention. However, the following embodiments are provided solely to facilitate a better understanding of the present invention and are not intended to limit the scope of the present invention. The embodiments are susceptible to various modifications, and thus the embodiments are not limited to the embodiments disclosed below and may be implemented in various forms.

[0148] Terms or words used in the specification and claims of the present invention are not to be construed as limited to their usual or dictionary meanings, and should be interpreted as meanings and concepts that conform to the technical idea of ​​the present invention based on the principle that the inventor can appropriately define the concept of the term to explain his or her own invention in the best way.

[0149] Throughout the specification of the present invention, when a part is said to "include" a certain component, this does not mean that other components are excluded, but rather that other components may be included, unless specifically stated otherwise.

[0150] Throughout the specification of the present invention, “A and / or B” means A or B, or A and B.

[0151]

[0152] Reference Example 1. Culture of bone marrow-derived macrophages

[0153] Macrophages were isolated from bone marrow cells of 7-week-old BALB / c mice and used. First, a culture medium for macrophages was prepared by mixing 10% L929 cell line culture medium with High Glucose DMEM (Biowest Inc., Nuaile, France) containing 10% FBS (Biowest Inc., Nuaile, France), 100 U / ml penicillin, and 100 μg / ml streptomycin (Biowest Inc., Nuaile, France). 10 ml of the above macrophage culture medium was added to a 90 × 15 mm petri dish (SPL life science, Pocheon, Korea), and the isolated macrophages were cultured for 3 days. Thereafter, 10 ml of the above macrophage culture medium was added, and the macrophages were differentiated and used in the experiment by culturing for 3 days.

[0154]

[0155] Reference Example 2. Preparation of 7H10 solid medium for culturing nontuberculous mycobacteria.

[0156] 450 ml of distilled water and Difco in a 1 liter Erlenmeyer flask TM 9.5 g of Middlebrook 7H10 Agar (BD bioscience, USA) powder was added. The Erlenmeyer flask was then sterilized using an autoclave at 121°C for 15 minutes. After cooling the sterilized 7H10 agar medium to approximately 60°C, 10% OADC was added and 23 ml was dispensed into each 90×15 mm petri dish (SPL life science). The solid medium was then used after drying for one day.

[0157]

[0158] Example 1. Confirmation of the efficacy of CD36 inhibitors in inhibiting the growth of nontuberculous mycobacteria.

[0159] To confirm the inhibitory effect of CD36 inhibitors on the growth of nontuberculous mycobacteria, experiments were conducted using macrophages infected with nontuberculous mycobacteria.

[0160] Macrophages differentiated by the method of Reference Example 1 were treated with Trypsin-EDTA (TE) to isolate the cells, and then 1.5 × 10 were seeded in a 48-well cell culture plate (SPL life science). 5 The cells were seeded at a concentration of 10 cells / well and cultured for 24 hours. Afterwards, the culture medium was removed and replaced with a culture medium containing 100 μM Sulfo-N-succinimidyl oleate (SSO, 11211; Cayman Chemical) and cultured for 4 hours. After 4 hours, the culture medium was removed and replaced with a 5% culture medium containing M. avium SMC#7 at a multiplicity of infection (MOI): 3 and incubated for 4 hours. Next, the culture medium containing the strain was removed, and a 5% culture medium containing 100 μM SSO was dispensed and cultured for 3 days.

[0161] Afterwards, the culture medium in the 48-well plate was removed and washed twice using DPBS (Biowest Inc.). The washed macrophages were treated with 200 μl per well of 1% Triton X-100 diluted to 0.05% to lyse the membrane of the macrophages for 10 minutes. The lysate released from the lysed macrophages was diluted 1 / 100 and 1 / 1000, and 50 μl per well was dropped onto the 7H10 solid medium prepared by the method of Reference Example 2, and cultured in a microbial incubator for approximately 10 days. After 10 days, the colony forming unit (CFU) was measured using the cultured bacteria to confirm the inhibition effect against the growth of nontuberculous mycobacteria.

[0162] Figure 1 is a graph confirming the growth inhibition efficacy of nontuberculous mycobacteria according to treatment with a CD36 inhibitor.

[0163] As shown in Figure 1, unlike the macrophage control group in which CFU increased 72 hours after M. avium SMC#7 infection, the macrophage experimental group treated with SSO showed no increase in CFU, confirming the growth inhibition effect of nontuberculous mycobacteria by the CD36 inhibitor.

[0164]

[0165] Example 2. Confirmation of the inhibitory efficacy of CD36 inhibitors against nontuberculous mycobacteria in a mouse model of nontuberculous mycobacteria-induced respiratory infection.

[0166] 2.1. Creation of a mouse model of respiratory infection induced by nontuberculous mycobacteria

[0167] Based on the fact that nontuberculous mycobacterial infections are common in women with low body mass index, a mouse model of nontuberculous mycobacterial-induced respiratory infection was created.

[0168] Figure 2 is a schematic diagram showing the production of a mouse animal model of respiratory infection induced by nontuberculous mycobacteria.

[0169] Referring to Fig. 2, female A / J mice were divided into a standard diet group, a low-protein diet group, and a CD36-administered low-protein diet group. The female A / J mice divided into each group were provided with a standard diet (20% P) and a low-protein diet (1% P) for 2 weeks. The standard diet group was provided with AIN-93G diet (DooYeol Biotech, Seoul, South Korea) containing 20.0% protein, 64.0% carbohydrate, and 7.0% fat, and the low-protein diet group was provided with a formulated diet (DooYeol Biotech, Seoul, South Korea) containing 1.2% protein, 81.8% carbohydrate, and 7.0% fat.

[0170] Afterwards, the mice were infected with Mycobacterium avium SMC#7 by air injection.

[0171] At week 5 post-infection, anti-CD36 antibody (αCD36, 10009893; Cayman Chemical) at 1 mg / kg was administered intraperitoneally (ip) twice a week for 5 weeks to the 1% P low-protein diet group. At week 10 post-infection, necropsy was performed, and lung tissue was used.

[0172]

[0173] 2.2. Confirmation of the growth inhibition effect of nontuberculous mycobacteria following anti-CD36 antibody administration

[0174] The lung tissue of the animal model obtained by the method of Example 2.1 was pulverized using sterilized PBS. The pulverized lysate was diluted 1 / 100, 1 / 1000, and 1 / 10000 in PBS, and 50 μl was dispensed per well onto the 7H10 solid medium prepared by the method of Reference Example 2. After culturing in a microbial incubator for 10 days, the number of cultured bacteria was measured. The measured number of bacteria was expressed as CFU relative to the weight of each lung tissue of the mouse.

[0175] Figure 3 is a graph showing CFU in lung tissue of mice infected with nontuberculous mycobacteria-induced respiratory infection.

[0176] As shown in Figure 3, the CFU in the lung tissue of the low-protein diet group increased compared to the standard diet group. In contrast, the CFU did not increase in the low-protein diet group administered αCD36, confirming the inhibitory efficacy of the CD36 inhibitor against nontuberculous mycobacteria.

[0177]

[0178] 2.3. Confirmation of the inhibitory effect of nontuberculous mycobacteria in lung tissue

[0179] RNA in situ hybridization (RNA-ISH) was performed using lung tissues of the animal model obtained by the method of Example 2.1 according to the manufacturer's instructions for the RNAscope™ Fluorescent V2 Assay kit. Specifically, lung perfusion of one lobe of mouse lung tissue was performed using sterile PBS. The lung tissue was fixed in 4-10% paraformaldehyde (PFA) for 24 hours and then embedded in paraffin. The fixed tissue was sectioned into 5 μM-thick sections, followed by deparaffinization using xylene and dehydration using an ethanol series. The sections were pretreated with RNAscope™ Peroxide for 10 minutes, and target retrieval was performed for 15 minutes using RNAscope™ Target Retrieve Reagent (Advanced Cell Diagnostics) at 95°C after pretreatment. Panmycobacterial 16S rRNA probes were manufactured by Advanced Cell Diagnostics, and the corresponding gene sequences were visualized by red fluorescence through sequential amplification steps. Lung tissues were measured using a confocal laser microscope (Zeiss LSM 710).

[0180] Figure 4 shows the results of fluorescent staining of lung tissue from a mouse infected with nontuberculous mycobacteria-induced respiratory infection.

[0181] As shown in Figure 4, the bacterial load in the low-protein diet group was confirmed to increase compared to that in the standard diet group. In the low-protein diet group administered with αCD36, a bacterial load similar to that in the standard diet group was confirmed, confirming the nontuberculous mycobacterial inhibition efficacy of the CD36 inhibitor.

[0182]

[0183] Example 3. Preparation and identification of sulfo-N-succinimidyl oleate (SSO) derivatives.

[0184] 3.1 Compound SSO-02: (S)-1-oleoyl-5-oxopyrrolidine-2-carboxylic acid

[0185] Compound SSO-02

[0186]

[0187]

[0188] <Manufacture of Compound SSO-02>

[0189]

[0190]

[0191] Compound A (L-Pyroglutamic acid; (S)-5-Oxo-2-pyrrolidinecarboxylic acid; CAS 98-79-3) 58 mg (0.45 mmol) was dissolved in 2 mL of THF solvent, and the temperature was lowered to 0 °C. Then, pyridine 0.04 mL (0.45 mmol) and compound B (Oleoyl chloride; CAS 112-77-6) (0.3 mmol) were added. The reaction mixture was stirred at room temperature for 16 hours and then distilled under reduced pressure. The obtained mixture was separated and purified by silica gel column chromatography (EtOAc:MeOH = 15:1 by volume) to obtain compound SSO-0257 mg (0.14 mmol, yield 48%).

[0192] 1 H NMR data were measured as follows:

[0193] 1H NMR (600 MHz, Chloroform-d) δ5.35-5.32 (m, 2H), 4.74-4.69 (m, 1H), 2.95-2.86 (m, 2H), 2.79-2.69 (m, 1H), 2.61-2.52 (m, 1H), 2.38-2.29 (m, 1H), 2.20-2.13 (m, 1H), 2.04-1.97 (m, 4H), 1.65-1.57 (m, 2H), 1.41-1.16 (m, 20H), 0.87 (t, J = 6.9 Hz, 3H).

[0194]

[0195] 3.2 Compound SSO-04: (S)-3-oleoyl-2-oxooxazolidine-4-carboxylic acid

[0196] Compound SSO-04

[0197]

[0198]

[0199] <Preparation of Compound SSO-04>

[0200]

[0201]

[0202] 126 mg (0.96 mmol) of compound C ((S)-2-oxooxazolidine-4-carboxylic acid; CAS 19525-95-2) was dissolved in 4 mL of THF solvent, cooled to 0 °C, and 0.31 mL (2.26 mmol) of Et3N and compound B (Oleoyl chloride; CAS 112-77-6) (0.56 mmol) were added. The reaction mixture was stirred at room temperature for 16 hours and then distilled under reduced pressure. The obtained mixture was separated and purified by silica gel column chromatography (EtOAc:MeOH = 20:1 volume ratio) to obtain 178 mg (0.45 mmol, yield 80%) of compound SSO-04.

[0203] 1 H NMR data were measured as follows:

[0204] 1 H NMR (600 MHz, DMSO-d6) δ5.35-5.30 (m, 2H), 4.76 (dd, J = 9.4, 3.3 Hz, 1H), 4.55 (t, J = 9.2 Hz, 1H), 4.34 (dd, J = 9.0, 3.3 Hz, 1H), 2.87-2.72 (m, 2H), 2.01-1.95 (m, 4H), 1.58-1.48 (m, 2H), 1.32-1.20 (m, 20H), 0.88-0.81 (m, 3H).

[0205]

[0206] Example 4. Confirmation of CD36 inhibitory efficacy of SSO derivatives

[0207] In order to confirm the CD36 inhibitory effect of the SSO derivative according to one aspect of the present invention, the fatty acid absorption capacity according to treatment with the SSO derivative was measured using macrophages.

[0208] Specifically, macrophages differentiated by the method of Reference Example 1 were treated with Trypsin-EDTA (TE) to isolate the cells, and then 1.5×10 were seeded in a 48-well cell culture plate (SPL life science). 5The cells were seeded at a concentration of 10 cells / well and cultured for 24 hours. Afterwards, the culture medium was removed and replaced with a culture medium containing 200 μM Sulfo-N-succinimidyl oleate (SSO, 11211; Cayman Chemical), 200 μM SSO-02 (Example 1), and 200 μM SSO-04 (Example 1), and cultured for 3 hours. Afterwards, the cells were washed with PBS and treated with 0.5 μg / mL of Green fluorescent labeled fatty acid (C16 bodypy; #D3821, Invitrogen™). After 1 hour of treatment, the Green fluorescence value in the cells was measured by flow cytometry. The results are shown in Fig. 5.

[0209] Figure 5 is a graph showing fatty acid absorption capacity according to treatment of an SSO derivative according to one aspect of the present invention.

[0210] As shown in Fig. 5, the SSO-02 and SSO-04 treatment groups exhibited better fatty acid absorption capacity than the SSO treatment group. The above results indicate that the SSO derivative according to one aspect of the present invention has CD36 inhibitory efficacy similar to or better than that of SSO.

[0211]

[0212] Example 5. Confirmation of the growth inhibition effect of nontuberculous mycobacteria by SSO derivatives.

[0213] In order to confirm the growth inhibitory effect of the SSO derivative according to one aspect of the present invention on nontuberculous mycobacteria, an experiment was conducted using macrophages infected with nontuberculous mycobacteria.

[0214] Specifically, macrophages differentiated by the method of Reference Example 1 were treated with Trypsin-EDTA (TE) to isolate the cells, and then 1.5×10 were seeded in a 48-well cell culture plate (SPL life science). 5The cells were dispensed at a concentration of 10 cells / well and cultured for 24 hours. Afterwards, the culture medium was removed and replaced with a culture medium containing 200 μM Sulfo-N-succinimidyl oleate (SSO, 11211; Cayman Chemical), 200 μM SSO-02 (Example 1), and 200 μM SSO-04 (Example 1), and cultured for 3 hours. After 3 hours, the culture medium was removed and replaced with a 5% culture medium containing M. aviumSMC#7 at a multiplicity of infection (MOI): 3, and reacted for 4 hours. Next, the culture medium containing the strain was removed, and a 5% culture medium containing 200 μM SSO, 200 μM SSO-02, and 200 μM SSO-04 was dispensed, and cultured for a total of 72 hours.

[0215] Afterwards, the culture medium in the 48-well plate was removed and washed twice using DPBS (Biowest Inc.). The washed macrophages were treated with 200 μl per well of 1% Triton X-100 diluted to 0.05% to lyse the membrane of the macrophages for 10 minutes. The lysate released from the lysed macrophages was diluted 1 / 100 and 1 / 1000, and 50 μl per well was dropped onto the 7H10 solid medium prepared by the method of Reference Example 2, and cultured in a microbial incubator for approximately 10 days. After 10 days, the colony forming unit (CFU) was measured using the cultured bacteria to confirm the inhibition effect on the growth of nontuberculous mycobacteria. The results are shown in Fig. 6.

[0216] Figure 6 is a graph confirming the growth inhibition efficacy of non-tuberculous mycobacteria according to treatment with an SSO derivative according to one aspect of the present invention.

[0217] As shown in Fig. 6, unlike the macrophage control group (untreated control group) in which CFU increased 72 hours after M. avium SMC#7 infection, CFU decreased in the SSO, SSO-02, and SSO-04 treatment groups. The SSO-02 treatment group showed a similar degree of bacterial growth inhibition efficacy to that of SSO, and the SSO-04 treatment group showed a higher bacterial growth inhibition efficacy than the SSO treatment group. The above results indicate that the SSO derivative according to one aspect of the present invention has excellent growth inhibition efficacy against nontuberculous mycobacteria.

[0218]

[0219] From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering its technical concept or essential characteristics. In this regard, it should be understood that the experimental examples and embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims and their equivalent concepts, rather than the detailed description above.

Claims

1. A compound of the following formula I, or a stereoisomer, racemate, solvate, or salt thereof: [Chemical Formula I] In the above formula, X is -CH2-, -O-, or -S-; R 1 Silver -H, C 1-6 Alkyl, C 1-6 is alkoxy or halogen; R 2 is -H, halogen, -OR 4 , -SR 4 , or -COOR 4 And, The above R 4 are each independently -H, C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 It is alkynyl; R 3 C is substituted or unsubstituted 8-22 Alkyl or C 8-22 It is alkenyl, C here 8-22 Alkyl or C 8-22 When alkenyl is substituted, C 8-22 Alkyl or C 8-22 Each hydrogen atom of the alkenyl is independently C 1-12 Alkyl, C 2-12 alkenyl, and C 2-12 It is substituted with one or more selected from the group consisting of alkynyl.

2. In the first paragraph, the R 3 A compound, or a stereoisomer, racemate, solvate, or salt thereof, which is an aliphatic chain of a saturated fatty acid having 8 to 22 carbon atoms or an unsaturated fatty acid having 8 to 22 carbon atoms.

3. In the second paragraph, the saturated fatty acid is selected from the group consisting of caprylic acid, pelargonic acid, capric acid, neodecanoic acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecanoic acid, palmitic acid, margaric acid, stearic acid, isostearic acid, nonadecylic acid, arachidic acid, heneicosylic acid, and behenic acid, or a compound, or a stereoisomer, racemate, solvate, or salt thereof.

4. In the second paragraph, the unsaturated fatty acid is lauroleic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, gadoleic acid, eicosenoic acid, erucic acid, linoleic acid, eicosadienoic acid, docosadienoic acid, α-linolenic acid, γ-linolenic acid, α-eleostearic acid, β-eleostearic acid, columbinic acid, pinolenic acid A compound, or a stereoisomer, racemate, solvate, or salt thereof, selected from the group consisting of acid, mead acid, eicosatrienoic acid, stearidonic acid, arachidonic acid, eicosatetraenoic acid, and docosatetraenoic acid.

5. In paragraph 1, R 2 A compound having the arrangement shown in the following chemical formula II, or a stereoisomer, racemate, solvate, or salt thereof: [Chemical Formula II] .

6. In paragraph 1, A compound selected from the group consisting of: or a stereoisomer, racemate, solvate, or salt thereof: (S)-1-oleoyl-5-oxopyrrolidine-2-carboxylic acid, (R)-1-oleoyl-5-oxopyrrolidine-2-carboxylic acid, (S)-3-oleoyl-2-oxooxazolidine-4-carboxylic acid and (R)-3-Oleoyl-2-oxooxazolidine-4-carboxylic acid.

7. A pharmaceutical composition for preventing or treating nontuberculous mycobacterial infection or nontuberculous mycobacterial lung disease, comprising an inhibitor of CD36 expression or activity.

8. In the 7th paragraph, the pharmaceutical composition comprises at least one selected from the group consisting of the following: (i) antisense nucleotides, small hairpin RNA (shRNA), small interfering RNA (siRNA), microRNA (miRNA), and ribozyme that complementarily bind to the mRNA of the CD36 gene; and (ii) Antibodies, antigen-binding fragments of antibodies, compounds, peptides, peptide mimetics, aptamers, and fusion proteins that bind to CD36 protein.

9. In paragraph 8, A pharmaceutical composition wherein the compound is sulfo-N-succinimidyl oleate (SSO) or a derivative thereof.

10. In paragraph 9, A pharmaceutical composition wherein the derivative of the above SSO is a compound according to any one of claims 1 to 6, or a stereoisomer, racemate, solvate, or salt thereof.

11. In paragraph 7, A pharmaceutical composition wherein the above CD36 expression or activity inhibitor inhibits the growth of nontuberculous mycobacteria by inhibiting fatty acid absorption.

12. In paragraph 7, The above nontuberculous mycobacteria are Mycobacterium avium (Mav), Mycobacterium abscessus subsp. abscessus (Mabc), Mycobacterium abscessus subsp. massiliense (Mmass), Mycobacterium abscessus subsp. boletii.bolletii), Mycobacterium Intracellurare, Mycobacterium chimaera, Mycobacterium Scrofulaceum, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium peregrinum, Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium Genevans, Mycobacterium simiae, Mycobacterium terrae, A pharmaceutical composition comprising at least one selected from the group consisting of Mycobacterium nonchromogenicum, Mycobacterium celatum, Mycobacterium gordonae, Mycobacterium szulgai, Mycobacterium mucogenicum, Mycobacterium xenopi, and Mycobacterium aubagnens.

13. In paragraph 7, A pharmaceutical composition, wherein the above infection is at least one selected from the group consisting of skin, soft tissue, and bone infections, lung diseases, lymphadenitis, and disseminated diseases.

14. In paragraph 7, A pharmaceutical composition, wherein the pharmaceutical composition further comprises an acid-fast bactericidal agent or an anti-tuberculosis agent, or is administered in combination with an acid-fast bactericidal agent or an anti-tuberculosis agent.

15. In paragraph 14, The above acid-fast bactericidal agents or antituberculosis agents include rifampicin, rifabutin, rifapentine, pyrazinamide, ciprofloxacin, capreomycin, fluoroquinolone, cycloserine, ethambutol, amoxicillin / clavulanate, ofloxacin, levofloxacin, isoniazid, streptomycin, kanamycin, prothionamide, moxifloxacin, amikacin, protionamide, A pharmaceutical composition comprising at least one selected from the group consisting of ethionamide, cycloserine, thioacetazone, clofazimine, a derivative of dianomidiphenylsulphone, clarithromycin, azithromycin, and linezolid.

16. A health functional food for preventing or improving nontuberculous mycobacterial infection or nontuberculous mycobacterial lung disease, comprising an inhibitor of CD36 expression or activity.

17. In the 16th paragraph, the CD36 expression or activity inhibitor comprises at least one selected from the group consisting of: (i) antisense nucleotides, small hairpin RNA (shRNA), small interfering RNA (siRNA), microRNA (miRNA), and ribozyme that complementarily bind to the mRNA of the CD36 gene; and (ii) Antibodies, antigen-binding fragments of antibodies, compounds, peptides, peptide mimetics, aptamers, and fusion proteins that bind to CD36 protein.

18. In paragraph 17, The compound is a health functional food that is sulfo-N-succinimidyl oleate (SSO) or a derivative thereof.

19. In paragraph 18, A health functional food, wherein the derivative of the above SSO is a compound according to any one of claims 1 to 6, or a stereoisomer, racemate, solvate, or salt thereof.

20. In paragraph 16, The above nontuberculous mycobacteria are Mycobacterium avium (Mav), Mycobacterium abscessus subsp. abscessus (Mabc), Mycobacterium abscessus subsp. massiliense (Mmass), Mycobacterium abscessus subsp. boletii.bolletii), Mycobacterium Intracellurare, Mycobacterium chimaera, Mycobacterium Scrofulaceum, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium peregrinum, Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium Genevans, Mycobacterium simiae, Mycobacterium terrae, A health functional food, wherein the health functional food comprises at least one selected from the group consisting of Mycobacterium nonchromogenicum, Mycobacterium celatum, Mycobacterium gordonae, Mycobacterium szulgai, Mycobacterium mucogenicum, Mycobacterium xenopi, and Mycobacterium aubagnens.

21. In paragraph 16, A health functional food, wherein the above infection is at least one selected from the group consisting of skin, soft tissue, and bone infections, lung diseases, lymphadenitis, and disseminated diseases.

Citation Information

Patent Citations

  • Composition for preventing or treating nontuberculous mycobacteria infections comprising inhibitors of CD36

    KR102629929B1

  • Cluster of differentiation 36 (CD36) as a therapeutic target for HIV infection

    US20150259429A1